Bio-Rad Laboratories Inc. - Ordinary Shares - Class A
BIO
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
44.3% downsideOvervalued by 44.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.01 Billion |
|---|---|
| Enterprise Value | $8.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $27.87 |
| Beta | 1.09 |
| Outstanding Shares | 26,958,000 |
Return
| Return on Equity | 2.46% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | 113.33% |
Valuation & Multiples
| P/E Ratio | 48.46 |
|---|---|
| PEG | -0.01 |
| Price to Sales | 3.11 |
| Price to Book Ratio | -2.71 |
| Enterprise Value to Revenue | 3.33 |
| Enterprise Value to EBIT | -8.3 |
| Enterprise Value to Net Income | 51 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 20.14% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.90%▼ 73.16% |
|---|---|
| Total Invested | $71.24M▼ 98.72% |
| Investors Holding | 17▼ 380.00% |
ESG Score
No data
About Bio-Rad Laboratories Inc.
CEO: Norman Schwartz Relevant Senate Committees
This powerful committee controls taxation and trade policy, directly impacting Bio-Rad's profitability through corporate tax rates and its global supply chain and sales through tariffs and trade agreements. It also influences overall healthcare spending.
This committee directly allocates discretionary federal spending. Its subcommittees determine precise funding for scientific research agencies (e.g., NIH, CDC) and government healthcare programs, which are major customers or funders of research using Bio-Rad's products.
This committee directly regulates the FDA (critical for clinical diagnostics) and NIH (a major funder of life science research, which uses Bio-Rad's instruments), providing direct oversight of key aspects of Bio-Rad's market and regulatory environment.